Company news

Clarity Pharmaceuticals Ltd. news in 2022

Clarity Pharmaceuticals Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Positive topline results from SAR-bisPSMA diagnostic trial

December 13, 2022

Managing Directors Presentation to AGM

November 23, 2022

Chairmans Address to Shareholders

November 23, 2022

IND approval from the FDA for theranostic SAR-Bombesin trial

November 20, 2022

Clarity Presentation -Bell Potter Healthcare Conference 2022

November 9, 2022

50% recruitment reached for Phase II prostate cancer trial

November 1, 2022

Corporate Presentation - Wilsons Drug and Device Conference

October 28, 2022

50% recruitment milestone reached for prostate cancer trial

October 26, 2022

First patient treated in therapeutic prostate cancer trial

October 6, 2022

First participant imaged in Phase II SAR-Bombesin trial

October 5, 2022

First participants imaged in SAR-Bombesin trial

September 13, 2022

Recruitment opens for Phase II trial in Prostate Cancer

September 4, 2022

Paediatric neuroblastoma trial advances to cohort 3

August 23, 2022

Imaging trial in prostate cancer opens for recruitment

August 22, 2022

Application for quotation of securities - CU6

July 5, 2022

Governance & Trading Policy Update

June 8, 2022

IND Approval by US FDA for Phase II SAR-Bombesin trial

June 5, 2022

Notification regarding unquoted securities - CU6

June 1, 2022

Presentation Jefferies Biotech Summit

May 27, 2022

First patient treated in the prostate cancer imaging trial

April 21, 2022

Clarity Half Yearly Report

February 28, 2022

Half Year Accounts

February 28, 2022

Update on China Grand Pharmaceutical and Healthcare Holdings

February 27, 2022

First patient treated in cohort 2 neuroblastoma trial

February 24, 2022

US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA

February 6, 2022

Clarity receives $3.26 million R&D tax incentive refund

February 3, 2022

SARTATE Neuroblastoma trial advances to cohort 2

January 31, 2022

Decks in 2022